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Abstract
Background & Aims:	Advances	in	direct-	acting	antiviral	treatment	of	HCV	have	rein-
vigorated	public	health	initiatives	aimed	at	identifying	affected	individuals.	We	evalu-
ated	the	possible	impact	of	only	diagnosed	and	linked-	to-	care	individuals	on	overall	
HCV	burden	estimates	and	identified	a	possible	strategy	to	achieve	the	WHO	targets	
by 2030.
Methods:	Using	a	modelling	approach	grounded	in	Italian	real-	life	data	of	diagnosed	
and	treated	patients,	different	linkage-	to-	care	scenarios	were	built	to	evaluate	poten-
tial	strategies	in	achieving	the	HCV	elimination	goals.
Results:	 Under	 the	 40%	 linked-	to-	care	 scenario,	 viraemic	 burden	would	 decline	
(60%);	however,	eligible	patients	to	treat	will	be	depleted	by	2025.	Increased	case	
finding	 through	 a	 targeted	 screening	 strategy	 in	 1948-	1978	birth	 cohorts	 could	
supplement	the	pool	of	diagnosed	patients	by	finding	75%	of	F0-	F3	cases.	Under	
the	 60%	 linked-	to-	care	 scenario,	 viraemic	 infections	 would	 decline	 by	 70%	 by	
2030	but	the	patients	eligible	for	treatment	will	run	out	by	2028.	If	treatment	is	to	
be	maintained,	 a	 screening	 strategy	 focusing	 on	 1958-	1978	 birth	 cohorts	 could	
capture	55%	of	F0-	F3	individuals.	Under	the	80%	linked-	to-	care	scenario,	screen-
ing	limited	in	1968-	1978	birth	cohorts	could	sustain	treatment	at	levels	required	to	
achieve	the	HCV	elimination	goals.
Conclusion:	In	Italy,	which	is	an	HCV	endemic	country,	the	eligible	pool	of	patients	to	
treat	will	run	out	between	2025	and	2028.	To	maintain	the	treatment	rate	and	achieve	
the	HCV	elimination	goals,	increased	case	finding	in	targeted,	high	prevalence	groups	
is	required.
K E Y W O R D S
chronic	infection,	HCV,	linkage	to	care,	WHO
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1  | INTRODUC TION
Hepatitis	C	virus	(HCV)	is	a	leading	cause	of	liver-	related	morbid-
ity	and	mortality	worldwide.	An	estimated	71	million	people	are	
affected	by	chronic	hepatitis	C	(CHC)	infection1	and	a	significant	
number	of	those	chronically	infected	progress	to	cirrhosis	or	liver	
cancer	 if	 left	 untreated.2,3	However,	 the	 development	 of	 direct-	
acting	 antiviral	 (DAA)	 therapy	 has	 revolutionized	 the	 approach	
to	 treatment	 and	 reinvigorated	public	health	 initiatives	 aimed	at	
identifying	 patients	 with	 CHC.	 Galvanized	 by	 these	 results,	 the	
World	 Health	 Organization	 (WHO)	 foresees	 the	 elimination	 of	
HCV	infection	by	2030	through	achieving	the	Global	Health	Sector	
Strategy	 Goals	 (GHSS)	 for	 Hepatitis.4	 While	 targeted	 screening	
programmes	for	high-	risk	populations	such	as	injection	drug	users	
are	necessary	for	elimination	of	Hepatitis	C,5,6	little	has	been	done	
to	understand	what	increases	in	diagnosis	and	treatment	are	nec-
essary	 in	 the	 general	 population	 of	 high	 endemic	 countries	 for	
achieving	 these	goals.	Given	 that	 the	use	of	DAAs	 regardless	of	
fibrosis	stage	is	cost-	effective,7	it	is	crucial	that	health	policies	ex-
pand	treatment	access	for	all	HCV-	infected	 individuals.	The	goal	
of	 this	study	was	 to	use	a	new	modelling	approach,	grounded	 in	
real-	life	cohort	data	of	diagnosed	and	treated	patients,	to	compare	
different	 linkage	 to	 care	 scenarios	 to	 the	 overall	 HCV-	infected	
population	 in	 Italy.	We	aimed	 to	evaluate	 the	possible	 impact	of	
only	linked-	to-	care	individuals	on	overall	HCV	burden	and	to	iden-
tify	a	possible	strategy	to	achieve	the	WHO	targets	by	2030.
2  | METHODS
2.1 | Study design
Two	Markov-	disease	burden	models	were	developed	to	assess	the	
current	and	future	HCV	disease	burden	 in	 Italy.	The	“Italy	Polaris”	
model	 is	 grounded	 in	 the	 natural	 history	 of	HCV	progression	 and	
forecasts	the	HCV	impact	on	the	general	population.	A	similar	HCV	
disease	burden	model,	grounded	in	the	current	distribution	of	linked-	
to-	care	patients	of	the	PITER	(Italian	Platform	for	the	Study	of	Viral	
Hepatitis	Therapies)	cohort	was	also	developed.8
2.1.1 | PITER cohort
PITER	is	an	ongoing	cohort	of	9145	(at	time	of	study)	consecutively	
enroled	patients	from	90	public,	general	hospitals	and	university	
medical	centres	distributed	across	Italy.	The	PITER	cohort	is	con-
sidered	a	representative	sample	of	linked-	to-	care	patients	with	no	
treatment	 access	 restrictions	 on	 the	 basis	 of	 healthcare	 system	
reimbursement	 criteria.8	 PITER	 aims	 to	 evaluate	 the	 expected	
impact	of	DAAs	on	 the	natural	 course	of	hepatitis	 infection	and	
on	long-	term	morbidity	and	mortality	in	a	real-	life	setting	in	Italy.	
The	 PITER	 inclusion	 criteria	 are:	 all	 HCV-	infected	 patients	 (any	
stage,	 any	 genotype,	 including	 HBV,	 HDV,	 or	 HIV	 co-	infection)	
at	least	18	years	of	age	consecutively	referred	to	outpatient	clin-
ics	of	 the	participating	 clinical	 centres	during	enrolment	phases,	
who	are	untreated	at	the	time	of	enrolment.	The	mean	age	of	en-
rolled	 patients	 is	 61	 (range	 18-	94)	 years	 of	 age	 and	 the	 ratio	 of	
males	 to	 female	 is	 1/1.2	 (55%	male).8	 The	 older	 age	 of	 patients	
enrolled	in	PITER	represents	the	cohort	effect	of	HCV	infection	in	
Italy.	Of	patients	enrolled	in	the	PITER	cohort	in	2016,	52%	were	
F0-	F3,	 38%	F4	 and	10%	had	 decompensated	 cirrhosis	 or	HCC.8 
Treatment	initiations	occurring	among	enrolled	patients	cover	the	
full	evolution	of	DAA	access	in	Italy	from	2014	on.
2.1.2 | AIFA treatment data
Real-	life	 reported	 treatment	 data	 were	 provided	 from	 January	
2015	through	August	2017	by	the	Italian	Medicines	Agency	(AIFA).9 
AIFA	reimbursement	criteria	 included	fibrosis	stage	≥F3	patients,	
patients	with	extrahepatic	manifestations	 in	any	stage	of	 fibrosis	
and	liver	transplant	recipients,	until	the	end	of	2016.	Beginning	in	
2017,	 treatment	was	 expanded	 to	 all	 patients	 independent	 of	 fi-
brosis	score.9
2.1.3 | Italy Polaris and PITER adjusted models
For	 this	 analysis,	 two	 separate	 models	 were	 constructed.	 First,	 a	
Markov	HCV	disease	 progression	model	 (the	 “Italy	 Polaris	model”)	
was	built	using	previously	described	methodology10	to	forecast	the	
annual	prevalence	of	chronic	HCV	infection	in	Italy	by	liver	disease	
stage,	sex	and	age.	In	this	model,	the	number	of	annual	historical	HCV	
incident	cases,	starting	in	1950,	and	their	sex	and	age	group	distribu-
tion	was	back-	calculated	 to	match	 the	modelled	prevalence	by	 sex	
and	age	group	in	2015	to	reported	estimates11	(Section	1	in	Appendix	
S1).	The	reported	number	of	annual	treated	patients	as	tracked	in	the	
AIFA	Monitoring	Registry	 for	DAAs9	was	 allocated	 to	 the	 age	 and	
liver	 disease	 stage	 of	 the	 eligible	 HCV-	infected	 population	 by	 the	
relative	 size	 of	 population	 in	 each	 treatment-	eligible	 disease	 stage	
Key Points
•	 In	 Italy,	 the	 eligible	 pool	 of	 chronic	 HCV	 infected	 pa-
tients	to	treat	will	run	out	between	2025-2028,	leaving	
a	significant	proportion	of	 infected	 individuals	undiag-
nosed	and	without	access	to	care.
•	 Increased	case	finding	in	high	prevalent	birth	cohorts	of	
the	 general	 population	 through	 targeted	 screening	
strategies	are	necessary	to	achieve	the	WHO	goals	for	
elimination	of	viral	hepatitis.
•	 If	the	treatment	rate	decreases	before	2025,	increased	
case	 finding	 in	 individuals	born	between	1948-1978	 is	
necessary	to	achieve	the	WHO	elimination	goals.	If	the	
treatment	rate	is	sustained	until	2028,	screening	strate-
gies	 focusing	 on	 individuals	 born	 between	 1958-1978	
are	warranted.
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(Table	1).	The	number	of	annual	treatments	initiated	within	each	dis-
ease	stage	was	uniformly	distributed	across	treatment-	eligible	ages.
Afterwards,	 the	 Italy	Polaris	model	was	adapted	to	 initiate	 the	
model	in	2015	(the	“PITER	adjusted	model”)	with	the	disease	stage,	
sex	and	age	group	distribution	of	linked-	to-	care	prevalent	cases	as	
reported	 in	PITER	(Section	2	 in	Appendix	S1).	Background	mortal-
ity	by	5-	year	age	and	sex	cohort,	standard	mortality	ratios	and	the	
future	incident	cases	were	applied	as	in	the	Italy	Polaris	model.	The	
number	of	 annual	 treatments	 initiated	 in	 this	model	was	 the	 real-	
life	number	of	treatments	with	DAAs	from	2015	to	August	2017	by	
disease	stage	and	age	as	provided	by	the	AIFA	Monitoring	Registry.9
2.2 | Statistical analysis
Two	general	 population	 scenarios	 describe	 the	 forecasted	disease	
burden	through	2030	and	three	scenarios	based	on	PITER	data	eval-
uate	the	impact	of	linkage	to	care	on	viraemic	prevalence	(Table	2).
2.2.1 | Scenarios—Italy Polaris Model
Base 2016
Represents	 the	2016	 standard	of	 care	 in	 Italy	 (treatment	of	 pa-
tients	with	fibrosis	stage	≥F3)	maintaining	the	same	fibrosis	stage,	
Italy specific parameters in 
model Year Value (Range) Source
Total	viraemic	population 2015 849	000	(371	000-	1	240	000) 13
Viraemic	prevalence 2015 1.39%	(0.6%-	2.00%) 13
Viraemic	diagnosed	population 2015 357	000	(255	000-	510	000) Expert	input
Annual	newly	linked	to	care	for	
treatmenta
2013 30 400 Expert	input
Annual	number	treated 2015 31 000 9
aAnnual	Newly	Linked	to	Care	for	Treatment	encompasses	those	newly	diagnosed	each	year.
TABLE  1 Key	inputs	of	the	disease	
burden model
TABLE  2  (A)	Inputs	by	scenario,	2015-	2030.	(B)	Inputs	of	the	WHO	Targets	scenario,	2015-	2030
A 2015 2016 2017 2018 2019 2020+
Annually	treated
Base	2016 31 000 33 700 29 500 25 300 21 100 16 900
PITER	(40%,	60%,	80%) — 33 700 33 700 33 700 33 700 33 700
Tx-	eligible	stages
Base	2016 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3 ≥F3
PITER	(40%,	60%,	80%) ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx-	eligible	ages
Base	2016 15-	64 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
PITER	(40%,	60%,	80%) 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
SVR
Base	2016 93% 93% 93% 93% 93% 93%
PITER	(40%,	60%,	80%) — 93% 95% 98% 98% 98%
B 2015 2016 2017 2020 2022 2025+
Annually	treated
WHO	targets 31 000 33 700 33 700 35 700 36 700 38 000
Newly	linked	to	carea
WHO	targets 30 400 30 400 30 400 33 400 35 400 36 400
Tx-	eligible	stages
WHO	targets ≥F3 ≥F3 ≥F0 ≥F0 ≥F0 ≥F0
Tx-	eligible	ages
WHO	targets 15-	64 15-	85+ 15-	85+ 15-	85+ 15-	85+ 15-	85+
SVR
WHO	targets 93% 93% 95% 95% 98% 98%
SVR,	sustained	virological	response;	Tx,	treatment;	WHO,	World	Health	Organization.
aAnnual	Newly	Linked	to	Care	for	Treatment	encompasses	those	newly	diagnosed	each	year.
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treatment	age	and	SVR	rate	assumptions	through	2030.	In	2016,	
30	400	patients	were	considered	 to	be	newly	 linked-	to-	care	 for	
treatment	 annually	 and	 33	700	 patients	were	 treated	 that	 year.	
As	no	screening	strategy	is	in	place	in	Italy,	the	number	of	treated	
patients	 was	 expected	 to	 decrease	 by	 half	 by	 2020	 due	 to	 the	
depleting	pool	of	eligible	patients	to	treat.12
WHO Targets
The	WHO	 Targets	 scenario	 identifies	 the	 expansion	 of	 diagnosis	
and	 treatment	 necessary	 to	 achieve	 the	WHO’s	 2030	 targets	 for	
incidence,	mortality	and	diagnosis	coverage	for	HCV	defined	in	the	
GHSS	on	Viral	Hepatitis.4
2.2.2 | Scenarios—PITER adjusted model
Utilizing	the	PITER	cohort	data,	three	scenarios	were	created	repre-
senting	different	assumptions	regarding	proportions	of	the	prevalent	
population	in	2015	being	diagnosed	and	under	care	(40%,	60%,	and	
80%	linked	to	care).	The	annual	number	of	patients	treated,	 fibro-
sis	restrictions,	ages	eligible	for	treatment	and	SVR	were	the	same	
between	the	three	scenarios	 (Table	2).	 In	each	PITER	scenario,	the	
number	of	patients	to	be	treated	annually	following	the	year	2017	
was	kept	constant.	Under	the	40%	linkage-	to-	care	scenario,	 it	was	
assumed	(given	expert	feedback),	that	40%	of	the	prevalent	popu-
lation	(357	000	patients)	in	Italy	in	2015	was	diagnosed	and	under	
care.13	 Since	 the	 exact	 number	 of	 patients	 linked-	to-	care	 remains	
unknown,	 the	 same	 scenario	was	 then	 run	 under	 the	 assumption	
of	60%	 (510	000	patients)	 and	80%	 (680	000	patients)	 linkage-	to-	
care.	The	80%	scenario	was	derived	from	from	a	recent	study	in	the	
Italian	general	population13	and	the	60%	scenario	was	chosen	as	the	
midpoint.
2.3 | Sensitivity analysis
To	 assess	 the	 effect	 of	 uncertainties	 in	 model	 inputs,	 we	 used	
Crystal	 Ball,	 a	Microsoft	 Excel	 (Microsoft	 Corporation,	 Redmond,	
WA,	USA)	add-	in	by	Oracle	(Oracle	Corporation,	Redwood	City,	CA,	
USA)	to	generate	95%	uncertainty	intervals	on	modelled	outcomes	
through	Monte	Carlo	simulation	(1000	simulations	per	analysis).	We	
used	 Beta-	PERT	 distributions	 for	 all	 uncertain	 inputs	 to	 estimate	
the	impact	on	total	viraemic	infections	in	2030.	The	key	drivers	for	
prevalence	uncertainties	used	in	the	sensitivity	analysis	are	reported	
in	the	Results	and	Section	1	in	Appendix	S1.	In	addition,	we	consid-
ered	how	the	variance	in	prevalence	affects	the	suggested	targeted	
screening	strategies.
3  | RESULTS
3.1 | Base 2016 (Italy Polaris Model)
There	were	an	estimated	849	000	(95%	UI:	371	000-	1	240	000)	in-
fected	individuals	in	2015.	The	forecasted	impact	of	each	scenario	
on	total	number	of	viraemic	infections,	HCV	liver-	related	morbidity	
and	mortality	were	compared	through	2030	(Figures	1	and	2).	Given	
the	 relatively	 large	number	of	patients	 treated	 in	 Italy,	 total	 infec-
tions	are	expected	to	decline	to	288	000	(95%	UI:	71	880-	424	640),	
or	 65%,	 by	2030.	DC	 cases	 are	 forecasted	 to	 decrease	75%	 from	
22	900	 (95%	 UI:	 4300-	46	700)	 in	 2015	 to	 6100	 (95%	 UI:	 100-	
15	300)	in	2030	(Figure	2).	HCC	cases	are	also	expected	to	decline	
from	14	000	(95%	UI:	3300-	35	100)	to	3800	(95%	UI:	60-	12	500)	by	
the	same	year.	HCV	liver-	related	mortality	is	expected	to	decline	by	
75%	from	11	300	(95%	UI:	2600-	19	600)	to	3100	(95%	UI:	50-	7000)	
deaths	by	2030.
3.2 | WHO targets (Italy Polaris Model)
In	 order	 to	 achieve	 the	 WHO	 GHSS	 targets,	 treatment	 was	 ex-
panded	to	38	000	patients	annually	by	2025;	restrictions	by	fibro-
sis	 stage	 were	 lifted,	 and	 SVR	 was	 increased	 incrementally	 over	
the	 next	 10	years	 to	 represent	 the	 higher	 efficacy	 of	 treatments	
in	coming	years	(Table	2b).	Total	HCV	viraemic	infections	and	HCV	
liver-	related	morbidity	 and	mortality	 are	 expected	 to	decline	 sub-
stantially,	by	95%,	90%	and	90%,	respectively,	by	2030	(Figure	2).
3.3 | PITER adjusted model, 40%, 60% and 80% 
linked- to- care patients
Given	 the	 40%	 linkage-	to-	care	 scenario,	 total	 viraemic	 infections	
would	decline	by	60%,	to	329	000	(95%	UI:	199	960-	365	960)	pa-
tients,	 by	 2030.	 However,	 the	 eligible	 patients	 to	 treat	 would	 be	
depleted	 by	 2025.	 Under	 the	 60%	 linkage-	to-	care	 scenario,	 the	
patients	 eligible	 for	 treatment	 would	 run	 out	 in	 2028.	 Total	 in-
fections	were	 expected	 to	 decline	 to	 less	 than	 260	000	 (95%	UI:	
F IGURE  1 Total	viraemic	infections	by	scenario,	2015-	2030.	
The	forecasted	total	number	of	viraemic	infections	by	Base	2016,	
PITER	linkage-	to-	care	and	WHO	Targets	scenarios	were	compared.	
By	2030,	total	viraemic	infections	are	expected	to	decline	due	
to	the	higher	treatment	rate	in	Italy.	However,	the	number	of	
remaining	infections	would	still	remain	high	in	each	scenario.	The	
WHO	Scenario	is	forecasted	to	have	the	largest	reduction	on	
overall	viraemic	infections
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127	900-	298	100)	by	the	same	year.	Under	the	80%	linkage-	to-	care	
scenario,	total	viraemic	infections	are	forecasted	to	decline	by	80%,	
from	849	000	 infections	 to	157	000	 (95%	UI:	99	380-	196	980)	by	
2030.	 The	 pool	 of	 eligible	 patients	 to	 treat	 is	 expected	 to	 be	 de-
pleted	by	2031	(Figure	1).
In	order	to	understand	the	age	distribution	of	the	eligible	infected	
individuals	 for	 treatment	 and	 to	 suggest	 strategies	 to	 increase	 case	
finding	for	different	linkage	to	care	scenarios,	the	model	estimates	the	
age	cohorts	with	the	highest	prevalence	of	asymptomatic	individuals,	as	
shown	in	Table	3.	Because	30%	of	advanced	stage	liver	disease	(fibro-
sis	stage	≥F3)	patients	are	considered	on	treatment;	by	2020,	approx-
imately	 70%	 of	 all	 infected,	 asymptomatic	 (F0-	F3)	 individuals	 would	
be	found	in	those	born	in	the	years	1948-	1978.	According	to	the	40%	
linked-	to-	care	scenario,	targeted	screening	strategies	in	the	1948-	1978	
birth	cohorts	could	be	 implemented	to	sustain	the	current	treatment	
rate.	If	60%	of	the	infected	population	are	linked-	to-	care,	then	screening	
fewer,	younger	birth	cohorts,	compared	to	the	40%	linked	to-care	sce-
nario,	specifically	those	born	in	the	years	1958-1978	(Table	3)	could	be	
useful	in	finding	at	least	30%	more	of	eligible	infected	F0-	F3	individuals.
3.4 | Sensitivity analysis
The	 model	 inputs	 that	 had	 the	 largest	 contribution	 to	 the	 uncer-
tainty	 in	 the	 Italy	Polaris	and	PITER	adjusted	models	are	shown	 in	
Figure	3A,B.	 For	 the	 Italy	 Polaris	model,	 the	 anti-	HCV	 prevalence	
in	 2015	 had	 the	 largest	 effect	 on	 the	 2030	 forecast	 of	 infections	
(Figure	3A).	There	would	be	approximately	535	000	remaining	virae-
mic	cases	in	2030,	as	compared	to	288	000,	if	there	were	1.24	mil-
lion	infections	in	2015.	More	than	89%	of	the	variability	in	the	2030	
forecasted	viraemic	infections	could	be	explained	by	the	estimated	
number	of	treated	patients.	If	the	eligible	linked	to	care	patients	were	
to	diminish	and	only	10	000	patients	would	be	eligible	for	treatment	
moving	forward	(rather	than	the	base	case	of	33,	700),	there	would	
be	 an	 estimated	260	000	viraemic	 cases	 in	 2030,	 almost	 100	000	
more	than	under	the	base	assumption.	The	top	five	factors	explained	
more	than	98%	of	the	variability	in	both	models	(Figure	3A,B).
In	addition,	we	assessed	how	prevalence	may	impact	the	differ-
ent	linkage-	to-	care	scenarios	and	the	related	case	finding	strategies.	
F IGURE  2 Liver-	related	morbidity	and	mortality	by	scenario,	2015-	2030.	The	forecasted	liver-	related	outcomes	by	Base	2016	and	WHO	
Targets	scenarios	were	compared.	By	2030,	all	HCV-	related	outcomes	are	expected	to	decline	due	to	the	higher	treatment	rate	in	Italy.	
However,	the	WHO	Scenario	is	forecasted	to	have	the	largest	impact	on	liver-	related	outcomes
TABLE  3 Distribution	of	F0-	F3	infected	cases	by	birth	year	in	
the	PITER	and	Italy	Polaris	models	in	2020
Birth year
Proportion of F0- F3 
infected cases in 
PITER Model (%)a
Proportion of F0- F3 
infected cases in Italy 
Polaris Model (%)a
1938-	1948 28 32
1948-	1958 35 42
1958-	1968 41 26
1968-	1978 23 17
1978-	1988 10 10
1988+ 5 8
aDoes	not	sum	to	100%	due	to	overlapping	birth	cohorts.
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Given	the	“low”	prevalence	rate,	the	eligible	patients	to	treat	would	
be	depleted	sooner	than	under	the	base	case	(4).	If	prevalence	was	
370	000	 infections	rather	than	the	849	000,	we	would	expect	the	
eligible	 patients	 to	 treat	 to	 be	 depleted	 by	 2022	 under	 the	 40%	
scenario;	and	in	2025	under	both	the	60%	and	80%	linkage	to	care	
scenarios.	However,	if	prevalence	was	more	than	a	million	patients,	
the	eligible	patient	pool	would	be	reduced	by	2027	under	the	40%	
linked-	to-	care	scenario.	Under	the	60%	and	80%	scenarios,	the	num-
ber	of	treated	patients	(approximately	35	000)	could	be	maintained	
annually	 through	 2030.	 The	 prevalence	 did	 not	 have	 a	 significant	
impact	on	the	identified	targeted	screening	strategies.	Assuming	a	
prevalence	of	approximately	370	000	cases,	we	estimate	a	less	than	
5%	change	in	the	distribution	of	F0-	F3	cases	by	birth	cohort.
4  | DISCUSSION
Italy	has	been	considered	the	country	with	the	highest	HCV	prev-
alence	 in	Western	Europe,	with	 the	peak	prevalence	 in	older	ages	
(>70	years).14-16	However,	many	studies	estimating	HCV	prevalence	
in	the	Italian	general	population	were	conducted	more	than	20	years	
ago	 and	 have	 shown	 regional	 variances.17	 The	 highest	 prevalence	
rates	have	been	 reported	 in	Southern	 Italy,	 though	many	of	 these	
earlier	studies	were	conducted	in	smaller,	more	rural	areas.	Recent	
studies	have	also	 reported	decreasing	 rates	of	HCV	prevalence	 in	
the	country.11,18,19
The	 limitation	of	HCV	 therapy	 is	 no	 longer	 treatment	 efficacy	
or	adherence,	but	the	identification	of	available	patients	to	treat.20 
As	with	prevalence,	the	availability	of	treatment	and	linkage	to	care	
varies	across	the	country.	Though	in	Italy	a	National	Hepatitis	Plan	
exists,	decentralized	models	of	HCV	care	persist	and	there	are	no	
uniform	 strategies	 across	 regional	 networks.	 Only	 2	 (Sicily	 and	
Veneto)	of	20	regions	throughout	Italy	have	developed	adequate	or-
ganizational	and	operational	politics	regarding	HCV	elimination.21-23 
Linkage	to	care	is	limited	in	that	no	enhanced	HCV	screening	and	di-
agnosis	is	implemented	in	the	country.	The	number	of	prescribers	is	
restricted	only	to	gastrointestinal	and	infectious	disease	specialists	
whom	are	limited	per	region.	It	was	recently	estimated	that	there	are	
1500	 residents	 per	 general	 practitioner	 in	 Italy,	 often	 curbing	 the	
availability	of	referral	and	linkage	to	care	to	a	specialist.13	In	addition,	
no	specific	strategies	for	marginalized	patients	and	at-	risk	groups	are	
implemented	at	the	national	level.
A	 true	 cascade	 of	 care	 for	HCV	 infection	 is	 lacking	 in	 Italy	 as	
the	number	of	patients	under	care	remains	uncertain.	Recent	studies	
F IGURE  3 Sensitivity	analysis	of	key	drivers	of	uncertainty	in	the	Italy	Polaris	model	(A)	and	in	the	PITER	adjusted	model	(B)	in	2030	
forecasted	viraemic	HCV	prevalence	(top	ten	shown).	The	labels	refer	to	the	high	and	low	value	of	the	variable	under	consideration.	For	
the	Italy	Polaris	model,	the	uncertainty	in	new	infections	considered	in	the	model	had	the	largest	effect	on	the	2030	forecast	of	prevalent	
viraemic	infections.	The	uncertainty	in	transition	probabilities	and	standardized	mortality	ratio	due	to	a	history	of	blood	transfusion	(see	
also	Section	1	in	Appendix	S1)	accounted	for	more	than	98%	of	all	explained	variation	in	the	Italy	Polaris	model	(A).	The	number	of	treated	
patients	explained	the	majority	of	the	variability	in	the	PITER	model.	More	than	89%	of	the	variability	in	the	2030	forecasted	viraemic	
infections	could	be	explained	by	the	estimated	number	of	treated	patients.	The	other	drivers	of	uncertainty	in	the	PITER	adjusted	model	are	
similar	to	Italy	Polaris	model	(B)
TABLE  4 Year	the	eligible	pool	of	patients	to	treat	is	estimated	
to	be	depleteda,	by	linkage	to	care	scenario	and	prevalence	range
Linkage to 
care scenario
Prevalence
Low (n) 371 000 Base (n) 849 000
High (n) 
1 240 000
40% 2022 2025 2027
60% 2025 2028 —
80% 2025 2031 —
aTo	assess	how	the	uncertainty	in	the	prevalence	estimate	impacts	the	
estimated	number	of	eligible	patients	to	treat,	 the	 linkage	to	care	sce-
narios	were	run	on	the	range	of	prevalence	values	(low:	371	000,	base:	
849	000,	high:	1	240	000)	to	assess	when	the	treated	patients	may	ex-
ceed	 eligible	 patients	 (“be	 depleted”).	 —Signifies	 that	 given	 the	 “high”	
prevalence	 estimate,	 the	 treated	 patients	 will	 not	 exceed	 eligible	 pa-
tients	and	treatment	levels	can	be	maintained	through	2030.
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reported	between	20%	and	80%	of	HCV+	individuals	are	aware	of	
their	 status.11,23	 This	 uncertainty	 has	 clear	 implications	 for	 treat-
ment,	as	 the	population	 first	needs	 to	be	 identified	 in	order	 to	be	
placed	 in	care.	While	the	real	number	of	 linked-	to-	care	patients	 in	
Italy	remains	unknown,	the	PITER	cohort	is	considered	a	representa-
tive	sample	of	linked-	to-	care	patients	in	Italy.8	The	PITER	linkage-	to-	
care	scenarios	are	based	on	the	characteristics	of	patients	enrolled	
in	PITER	and	estimates	different	possible	proportions	of	the	“tip of 
the iceberg.”	Extrapolating	the	age	and	fibrosis	stage	distribution	of	
current	linked-	to-	care	patients	(PITER	model)	to	the	general	popu-
lation	in	Italy	(Polaris	model)	 is	useful	for	understanding	what	may	
occur	 in	 the	overall	 infected	population	 if	 current	HCV	trends	are	
to	remain	at	current	levels.	As	seen	in	the	Base	2016	Scenario,	the	
WHO	goal	of	reducing	HCV	liver-	related	deaths	by	65%	by	2030	is	
achievable	in	Italy	if	the	treatment	rate	is	maintained	at	current	lev-
els.	However,	in	the	40%	and	60%	linkage-	to-	care	scenarios,	given	
the	same	number	of	treated	patients	through	2030,	the	eligible	pool	
of	patients	 to	be	 treated	would	 run	out	between	2025	and	2028,	
leaving	a	significant	proportion	of	infected	individuals	undiagnosed	
and	without	access	to	care,	as	is	shown	in	Figure	1.
Considering	the	cohort	effect	of	HCV	infection	in	Italy	and	low	
rates	of	 injection	drug	use,	 the	younger	cohorts	 (1988+)	are	those	
with	 the	 lowest	 prevalence	 of	HCV	 infection	 in	 Italy.	We	 did	 not	
consider	possible	screening	strategies	for	individuals	born	in	1935-	
1948	as	the	natural	depletion	of	the	virus	in	those	individuals	was	as-
sumed.	This	modelling	estimates	that	more	than	70%	of	the	infected	
(F0-	F3)	individuals,	those	that	are	most	often	asymptomatic	and	un-
diagnosed	 (the	underwater	portion),	were	within	 the	1948	to	1978	
birth	cohorts	in	2020	(Table	3).	This	signifies	a	potential	need	to	in-
crease	case	finding	in	these	individuals	if	the	treatment	rate	starts	
to	 decrease	 prior	 to	 the	 year	 2025	 (40%	 linked	 to	 care	 scenario).	
Similarly,	though	approximately	75%	of	individuals	with	chronic	HCV	
in	the	United	States	are	within	the	1945-	1965	birth	cohort,	screen-
ing	in	this	population	is	not	systematically	done	and	a	large	portion	
of	infected	individuals	fall	outside	of	this	cohort.24 If	60%	of	the	in-
fected	population	is	linked-	to-	care	then	the	treatment	rate	could	be	
sustained	until	the	year	2028.	Since	older	individuals	are	more	likely	
to	already	be	linked-	to-	care,	a	specific	increased	case	finding	strat-
egy,	focusing	on	individuals	born	in	years	1958-	1978,	could	be	useful	
in	finding	around	40%	of	eligible	infected	F0-	F3	patients.
The	PITER	adjusted	model	refers	to	a	population	with	a	mean	age	
of	59	years,	which	in	part	reflects	that	of	populations	in	other	parts	
of	the	world	that	have	similar	epidemiological	characteristics	(ie	indi-
viduals	infected	previously	through	blood	transfusion	or	nosocomial	
transmission	with	historical	trends	of	high	incidence	of	infection).25 
As	 seen	 in	 this	modelling	 study,	 the	 rate	 of	 treatment	 uptake	will	
decline	 unless	 screening	 and	 linking	 diagnosed	 patients	 to	 care	 is	
improved.	 In	 the	country	of	Georgia,	one	of	 the	nine	countries	on	
track	 to	achieve	 the	WHO	Targets	by	2030,	 the	number	of	newly	
diagnosed	patients	entering	the	national	treatment	programme	has	
fallen	in	the	past	year,	suggesting	that	identification	and	linkage-	to-	
care	of	HCV-	infected	patients	in	the	country	might	be	slowing.26,27 
The	potential	 targeted	screening	strategies	 that	were	produced	 in	
this	analysis	are	useful	tools	that	can	be	used	in	countries	with	com-
parable	HCV	epidemiology.	A	similar	approach	can	also	be	used	for	
countries	with	different	HCV	epidemiology,	in	that	it	addresses	the	
improvement	of	diagnosis	and	 the	 linkage	 to	care—key	 factors	 for	
achieving	the	elimination	goals.28,29
Several	 limitations	 of	 the	 analysis	 exist.	 This	 analysis	 was	 not	
focused	on	treatment	as	prevention.	While	neither	disease	burden	
model	dynamically	considers	new	infections	nor	reinfections	in	the	
population,	the	high	treatment	rate	in	Italy	coupled	with	the	reduced	
treatment	 restrictions	 exceeds	 the	 proportion	 required	 for	 treat-
ment	 when	 compared	 to	 other	 dynamic	 models.30-32	 In	 addition,	
although	the	PITER	cohort	is	considered	reasonably	representative	
of	 those	 receiving	 care	 across	 the	 country,	 the	PITER	model	 uses	
a	 disease	 stage	 distribution	 based	 on	 a	 small	 proportion	 (9145	 vs	
357	000)	 of	 diagnosed	 and	 linked-	to-	care	 patients.	 The	 true	 pro-
portion	of	the	linked-	to-	care	population	in	Italy	is	unknown.	While	
rates	of	 up	 to	80%	have	been	 reported,11	 experts	 involved	 in	 the	
analysis	have	suggested	that	40%	of	the	total	infected	population	is	
linked-	to-	care.	To	address	this	uncertainty,	we	presented	the	PITER	
analysis	 under	 three	 scenarios	 of	 40%,	 60%	 and	 80%	 linkage-	to-	
care.	 In	addition,	we	evaluated	 the	 impact	of	 this	uncertainty	and	
found	 the	 percent	 change	 in	 the	 linked-	to-	care	 population	 had	 a	
smaller	influence	on	viraemic	prevalence	in	2030	than	other	factors	
(Figure	2A,B).	 Lastly,	 the	 variance	 in	 prevalence	 had	 limited	 influ-
ence	on	the	proportion	of	F0-	F3	patients	identified	and	would	not	
impact	the	screening	strategies	discussed.
This	analysis	highlights	that	Italy	is	on	track	to	meeting	the	WHO	
target	of	65%	reduction	 in	 liver-	related	mortality	by	2030.	However,	
given	the	same	number	of	annually	treated	patients	through	2030,	the	
eligible	 pool	 of	 patients	 to	 be	 treated	would	 run	 out	 between	2025	
and	2028,	 leaving	a	significant	proportion	of	 infected	 individuals	un-
diagnosed	and	without	access	to	care.	Increased	case	finding	through	
potential	 targeted	 screening	 strategies	 are	 necessary	 to	 achieve	 the	
WHO	goals.	This	modelling	analysis	is	a	useful	tool	that	can	be	used	by	
different	countries	to	develop	screening	strategies	for	HCV	elimination.
ACKNOWLEDG EMENTS
The	authors	thank	the	PITER	collaborating	group	available	at	www.
progettopiter.it;	 Center	 for	 Disease	 Analysis	 Foundation’s	 Polaris	
Observatory,	 which	 collaborated	 on	 this	 project	 on	 a	 voluntary	
basis;	Antonietta	Coratrella	and	 Italian	Drug	Agency	 for	providing	
detailed	DAA	treatment	data	used	in	this	study.
CONFLIC T OF INTERE S T
The	authors	do	not	have	any	disclosures	to	report.
ORCID
Loreta A. Kondili  http://orcid.org/0000-0003-2656-224X 
Sarah Robbins  http://orcid.org/0000-0002-0455-644X 
     |  9KONDILI et aL.
Anna L. Zignego  http://orcid.org/0000-0002-8552-4166 
Pietro Lampertico  http://orcid.org/0000-0002-1026-7476 
Alessandro Federico  http://orcid.org/0000-0002-0885-0793 
Pietro Andreone  http://orcid.org/0000-0002-4794-9809 
Maria G. Quaranta  http://orcid.org/0000-0002-1077-1488 
Stefano Vella  http://orcid.org/0000-0003-2347-5984 
Antonio Craxì  http://orcid.org/0000-0002-4480-9544     
R E FE R E N C E S
	 1.	 The	Polaris	Observatory	HCV	Collaborators.	Global	prevalence	and	
genotype	distribution	of	hepatitis	C	virus	infection	in	2015:	a	mod-
elling	study.	Lancet Gastroenterol Hepatol.	2017;2:161-176.
	 2.	 WHO.	Global	Hepatitis	Report	2017.	http://apps.who.int/iris/bitst
ream/10665/255016/1/9789241565455-eng.pdf?ua=1.	 Accessed	
November	10,	2017.
	 3.	 Shepard	CW,	Finelli	L,	Alter	MJ.	Global	epidemiology	of	hepatitis	C	
virus	infection.	Lancet Infect Dis.	2005;5:558-567.
	 4.	 WHO.	Global	Health	Sector	Strategy	on	Viral	Hepatitis	2016-2021.	
http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-
2016.06-eng.pdf?ua=1.	Accessed	November	10,	2017.
	 5.	 Hellard	 M,	 Doyle	 JS,	 Sacks-Davis	 R,	 Thompson	 AJ,	 McBryde	 E.	
Eradication	 of	 hepatitis	 C	 infection:	 the	 importance	 of	 targeting	
people	who	inject	drugs.	Hepatology.	2014;59:366-369.
	 6.	 Lazarus	 JV,	Wiktor	 S,	 Colombo	M,	 Thursz	M,	 EASL	 International	
Liver	Foundation.	Micro-	elimination	–	a	path	to	global	elimination	
of	hepatitis	C.	J Hepatol.	2017;67:665-666.
	 7.	 Kondili	LA,	Romano	F,	Rolli	FR,	et	al.	Modelling	cost-	effectivness	
and	health	gains	of	a	“universal	vs	“prioritized”	HCV	treatment	pol-
icy	in	a	real-	life	cohort.	Hepatology.	2017;66:1814-1825.
	 8.	 Kondili	 LA,	 Vella	 S,	 PITER	 Collaborating	 Group.	 PITER:	 an	 ongo-
ing	nationwide	study	on	the	 real-	life	 impact	of	direct	acting	anti-
viral	based	treatment	for	chronic	hepatitis	C	in	Italy.	Dig Liver Dis. 
2015;47:741-743.
	 9.	 Agenzia	 Italiana	del	Farmacia.	www.aifa.gov.it.	Accessed	October	
30,	2017.
	10.	 Razavi	H,	Waked	I,	Sarrazin	C,	et	al.	The	present	and	future	disease	
burden	of	hepatitis	C	virus	(HCV)	infection	with	today’s	treatment	
paradigm.	J Viral Hepat.	2014;21(Suppl	1):34-59.
	11.	 Andriulli	A,	 Stroffolini	T,	Valvano	MR,	et	 al.	Declining	prevalence	
and	 increasing	 awareness	of	hepatitis	C	virus	 infection	 in	 Italy:	 a	
population-	based	survey.	Eur J Intern Med.	2018;53:79-84.
	12.	 National	 Academies	 of	 Sciences,	 Engineering,	 and	 Medicine.	 A 
National Strategy for the Elimination of Hepatitis B and C: Phase 
Two Report.	 Washington,	 DC:	 The	 National	 Academies	 Press;	 
2017.
	13.	 Gardini	 I,	Bartoli	M,	Conforti	M,	Mennini	FS,	Marcellusi	A,	Lanati	
E.	 HCV-	Estimation	 of	 the	 number	 of	 diagnosed	 patients	 eligible	
to	the	new	anti-	HCV	therapies	in	Italy.	Eur Rev Med Pharmacol Sci. 
2016;20:7-10.
	14.	 Guadagnino	V,	Stroffolini	T,	Rapicetta	M,	et	al.	Prevalence,	risk	fac-
tors	and	genotype	distribution	of	hepatitis	C	virus	infection	in	the	
general	 population:	 a	 community	 based	 survey	 in	 Southern	 Italy.	
Hepatology.	1997;26:106-111.
	15.	 Maio	G,	D’Argenio	P,	Stroffolini	T,	et	al.	Hepatitis	C	virus	infection	
and	alanine	transaminase	levels	in	the	general	population:	a	survey	
in	a	Southern	Italian	town.	J Hepatol.	2000;33:116-120.
	16.	 Bellentani	S,	Pozzato	G,	Saccoccio	G,	et	al.	Clinical	course	and	risk	
factors	of	hepatitis	C	virus	related	liver	disease	in	the	general	pop-
ulation:	report	from	the	Dionysos	study.	Gut.	1999;44:874-880.
	17.	 Marascio	 N,	 Liberto	 M,	 Barreca	 G,	 et	 al.	 Update	 on	 epidemiol-
ogy	of	HCV	in	Italy:	focus	on	the	Calabria	Region.	BMC Infect Dis. 
2014;14(Suppl	5):S2.
	18.	 Guadagnino	V,	Stroffolini	T,	Caroleo	B,	et	al.	Hepatitis	C	virus	infec-
tion	in	an	endemic	area	of	Southern	Italy	14	years	later:	evidence	
for	a	vanishing	infection.	Dig Liver Dis.	2013;45:403-407.
	19.	 Reau	N.	HCV	testing	and	linkage	to	care:	expanding	access.	Clin Liv 
Dis.	2014;4:31-34.
	20.	 National	Hepatitis	 Plan.	 Piano	 nazionale	 per	 la	 prevenzione	 delle	
epatiti	 virali	 da	 virus	 B	 e	 C	 (PNEV).	 http://www.salute.gov.it/
imgs/C_17_pubblicazioni_2437_allegato.pdf.	 Accessed	 April	 27,	
2018.
	21.	 Alberti	A.	Eradication,	elimination,	or	disease	control	of	Hepatitis	
C.	2017.	http://www.webaisf.org/media/37946/alberti_da_pubbli-
care.pdf.	Accessed	April	27,	2018.
	22.	 The	Italian	Liver	Patients’	Association	(EpaC).	https://www.epac.it/.	
Accessed	April	27,	2018.
	23.	 Scognamiglio	P,	Piselli	P,	Fusco	M,	et	al.	Declining	unawareness	of	
HCV-	infection	parallel	to	declining	prevalence	 in	Southern	Italy.	J 
Med Virol.	2017;89:1691-1692.
	24.	 Shiffman	ML.	Universal	screening	for	chronic	hepatitis	C	virus.	Liv 
Int.	2016;36:62-66.
	25.	 Smith	BD,	Beckett	GA,	Yartel	A,	Holtzman	D,	Patel	N,	Ward	JW.	
Previous	exposure	to	HCV	among	persons	born	during	1945-	1965:	
prevalence	and	predictors,	United	States,	1999-	2008.	Am J Public 
Health.	2014;104:474-481.
	26.	 Nasrullah	M,	 Sergeenko	 D,	 Gvinjilia	 L,	 et	 al.	 The	 role	 of	 screen-
ing	 and	 treatment	 in	 national	 progress	 toward	 hepatitis	 C	 elim-
ination	 —	 Georgia,	 2015–2016.	 MMWR Morb Mortal Wkly Rep. 
2017;66:773-776.
	27.	 Gvinjilia	L,	Nasrullah	M,	Sergeenko	D,	et	al.	National	progress	to-
ward	hepatitis	C	elimination	—	Georgia,	2015–2016.	MMWR Morb 
Mortal Wkly Rep.	2016;65:1132-1135.
	28.	 Chak	 E,	 Talal	 AH,	 Sherman	 KE,	 Schiff	 ER,	 Saab	 S.	 Hepatitis	 C	
virus	 infection	 in	 USA:	 an	 estimate	 of	 true	 prevalence.	 Liver Int. 
2011;31:1090-1101.
	29.	 Deuffic-Burban	 S,	Deltenre	 P,	 Buti	M,	 et	 al.	 Predicted	 effects	 of	
treatment	 for	 HCV	 infection	 vary	 among	 European	 countries.	
Gastroenterology.	2012;143:974-985.
	30.	 Scott	N,	McBryde	ES,	Thompson	A,	Doyle	JS,	Hellard	ME.	Treatment	
scale-	up	to	achieve	global	HCV	incidence	and	mortality	elimination	
targets:	a	cost-	effectiveness	model.	Gut.	2017;66:1507-1515.
	31.	 Martin	NK,	Vickerman	P,	Grebely	 J,	et	al.	Hepatitis	C	virus	 treat-
ment	 for	 prevention	 among	 people	 who	 inject	 drugs:	 modeling	
treatment	scale-	up	in	the	age	of	direct-	acting	antivirals.	Hepatology. 
2013;58:1598-1609.
	32.	 Hellard	ME,	 Jenkinson	R,	Higgs	P,	et	al.	Modelling	antiviral	 treat-
ment	 to	 prevent	 hepatitis	 C	 infection	 among	 people	 who	 inject	
drugs	in	Victoria,	Australia.	Med J Aust.	2012;196:638-641.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article.	
How to cite this article:	Kondili	LA,	Robbins	S,	Blach	S,	et	al.;		
Forecasting	Hepatitis	C	liver	disease	burden	on	real-	life	data.	
Does	the	hidden iceberg	matter	to	reach	the	elimination	
goals?	Liver Int. 2018;00:1–9. https://doi.org/10.1111/
liv.13901
